Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 1025 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Death Rates from Ovarian Cancer will Fall in the EU and... January 25, 2022 How to Maintain Your Sexual Health During and After Lung Cancer November 10, 2020 177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive... September 2, 2025 Prospective Evaluation of Benefit in Patients with Advanced Cancer Treated with... February 8, 2023 Load more HOT NEWS Withdrawal of Application to Change the Marketing Authorisation for Atezolizumab N-of-1 Tailored Combination Therapy Matched to the Molecular Alterations, Facilitated by... Immune Responses Similar for Adjuvanted and Standard Dose Influenza Vaccines for... How Clinical Trials Can Lead to Life-Saving Treatment: The TAPUR Trial...
